Salvatore Bonvegna

Real-world neuropsychiatric safety profile of foslevodopa/foscarbidopa infusion in advanced Parkinson's disease

Abstract Background To describe demographic, clinical, and neuropsychiatric safety outcomes in a cohort of PD patients treated with LDp/CDp infusion in a real-world setting. Methods We retrospectively analyzed a database of 77 consecutive PD patients treated with LDp/CDp at two I...